Analysts have been eager to weigh in on the Healthcare sector with new ratings on Angion Biomedica (ANGN), Leap Therapeutics (LPTX) and Adverum Biotechnologies (ADVM).
Angion Biomedica (ANGN)
In a report released today, Justin Kim from Oppenheimer initiated coverage with a Buy rating on Angion Biomedica and a price target of $38.00. The company’s shares closed last Monday at $19.92.
According to TipRanks.com, Kim is a 5-star analyst with an average return of 43.6% and a 72.1% success rate. Kim covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Aurinia Pharmaceuticals, and Aldeyra Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Angion Biomedica with a $59.33 average price target, implying a 182.4% upside from current levels. In a report released yesterday, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $100.00 price target.
See today’s analyst top recommended stocks >>
Leap Therapeutics (LPTX)
In a report released today, David Novak from Raymond James maintained a Buy rating on Leap Therapeutics, with a price target of $3.50. The company’s shares closed last Monday at $2.43.
According to TipRanks.com, Novak is a 4-star analyst with an average return of 18.8% and a 54.9% success rate. Novak covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Ziopharm Oncology, and Zymeworks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Leap Therapeutics with a $4.25 average price target.
Adverum Biotechnologies (ADVM)
Raymond James analyst Dane Leone maintained a Hold rating on Adverum Biotechnologies yesterday. The company’s shares closed last Monday at $13.32.
According to TipRanks.com, Leone is a 5-star analyst with an average return of 18.2% and a 65.8% success rate. Leone covers the Healthcare sector, focusing on stocks such as Tarsus Pharmaceuticals, Allogene Therapeutics, and Ayala Pharmaceuticals.
Currently, the analyst consensus on Adverum Biotechnologies is a Moderate Buy with an average price target of $13.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
